Todd C. Zion AKSTON BIOSCIENCES CORPORATION |
Todd C. Zion, Ph.D., is the Co-founder, President and CEO of Akston Biosciences
Corporation, which is developing an injectable therapy for antigenspecific
prevention of Type 1 Diabetes. Prior to starting Akston Biosciences,
Zion founded SmartCells, Inc. to develop SmartInsulin, the first glucose-regulated,
injectable formulation for treating diabetes. As SmartCells’ President
and CEO, Zion was instrumental in raising $10 million in equity financing
and $10 million in grants to support research and clinical development.
Merck and Co. acquired SmartCells for over $500 million in cash and clinical
milestone payments. Prior to enrolling at MIT, he worked as a polymer
development engineer at Eastman Kodak. Zion graduated from Cornell
University summa cum laude with a B.S. in Chemical Engineering. He is
currently an Associate Director at MIT’s Venture Mentoring Service and also
serves on a number of advisory boards including those of the Beth Israel
Deaconess Medical Center, Joslin Diabetes Center, and the Cornell Engineering
College Council. He is also active in his community serving as the head
of Devereux School and President of Dollars for Scholars.
72 Nanepashemet St.
Marblehead, MA 01945
857 389-2273
todd@toddzion.com